2024-12-01-艾昆纬-加拿大糖尿病和肥胖症的药物治疗-IQVIA关于2019-2023年药物利用数据的独立报告（英）_12页_1mb

Diabetes and Obesity Overview: Diabetes is a chronic condition affecting insulin production or usage, with Type 1 (5-10% of cases) and Type 2 (90-95%) being the main types. Obesity is a risk factor for Type 2 diabetes. In Canada, diabetes prevalence increased from 7.6% in 2019 to 9.4% in 2023, and obesity from 0.2% to 1.3%. Diabetes was more prevalent in men (10.3%) than women (8.6%) in 2023.

Trends and Treatments: Drug treatments are increasingly used, with Metformin remaining the most prescribed medication. GLP-1 receptor agonists showed the fastest growth. Obesity medications saw a significant increase, from 72,228 users in 2019 to 521,739 in 2023. Treatments include insulin, Biguanide (metformin), SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 agonists.

Provincial and Demographic Variations: All provinces saw a rise in prevalence, with the Atlantic provinces highest at 11.1% in 2023. Women were more likely to use obesity medications (2.0%) than men (0.6%). Age-wise, diabetes prevalence increased across groups, peaking in older adults (e.g., men 65+ in Ontario at 30+%). Obesity medication use was highest in Alberta among middle-aged women.

Prescriber Statistics: General practitioners issued the majority of prescriptions for both conditions. Endocrinologists and internal medicine specialists played smaller roles in provincial data.

Recommendations: Strengthen coordination between governments, healthcare providers, and communities for early detection and management. Use data analytics to track trends and inform targeted interventions. Integrate prescription data with other databases for better care and surveillance.

Methodology and Limitations: Based on anonymized, community pharmacy prescription data from 2019-2023, covering ~80% of dispensing. Data excludes undispensed, hospital/prison prescriptions, unconsumed meds, or diagnoses. Limitations include potential underestimation and lack of clinical indication details.